BCMA / CD19

Class

Cell therapy (compound CAR-T co-expressing membrane-bound IL-15/IL-15 sushi domain)

Pathway

T-cell-mediated killing of BCMA+/CD19+ cells with IL-15-driven persistence

This mechanism describes a chimeric antigen receptor (CAR) T-cell therapy engineered to recognize two surface proteins, BCMA and CD19, using two independent CAR constructs on the same T cell (a compound CAR). BCMA is expressed on mature plasma cells and is the principal driver-associated antigen in multiple myeloma. CD19 marks earlier B-lineage cells, including a rare clonal population thought to seed and replenish myeloma. Targeting both antigens aims to eliminate the visible plasma-cell tumor burden while also clearing the upstream clonal reservoir that a BCMA-only therapy might leave behind, potentially delaying relapse. The T cells are further engineered to co-express a membrane-bound form of interleukin-15 (IL-15) fused to its receptor sushi domain, delivering a localized growth and survival signal directly to the engineered cells. This is intended to improve their persistence and functional fitness after infusion without releasing IL-15 systemically, which would risk broader immune activation. This general strategy—engineered lymphocytes redirected to kill malignant cells via antigen recognition, reinforced by built-in cytokine support—is broadly relevant to hematologic malignancies, particularly multiple myeloma and B-cell lymphomas, where relapse driven by antigen-low or antigen-negative tumor subpopulations remains a central challenge.